Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 4 of 4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Гепатитийн вирусийн шалтгаант элэгний архаг үрэвслийн үед бөөрний түүдгэнцэрийн үйл ажиллагаа өөрчлөгдөх нь
    (2024-01-21)
    Suriga
    ;
    Suriguga
    ;
    Ц.Сарнай
    ;
    Б.Батболд
    Үндэслэл: Гепатит В вирус (ГВВ) болон гепатит С вирус (ГСВ) нь цочмог болон архаг Гепатит, элэгний хатуурал, цаашлаад элэгний хорт хавдарт хүргэдэг гол шалтгаан бөгөөд эмнэлзүйд элэгний, элэгний бус шинжүүд илэрдэг. Зорилго: Гепатитын вирусийн халдварын үед элэгний фиброзын зэргийг бөөрний түүдгэнцрийн шүүлтийн хурд буурахтай уялдуулан судлах. Арга, аргачлал: Судалгааг аналитик судалгааны эмнэлэгт суурилсан ретроспектив когорт загвараар гүйцэтгэв. Судалгааны хүн амыг БНХАУ-ын Бугат хотын эмнэлэгт 2022 оны 09 сараас 2023 оны 09 сар хүртэл ГBB/ГСВ-ийн архаг халдвар батлагдсан 200 өвчтөнүүдийн мэдээллийг санамсаргүй түүврийн аргаар цуглуулж биохимийн бүрэн автомат анализатор ашиглан өвчтөний элэг, бөөрний үйл ажиллагааг тодорхойлсон. Үр дүн: Судалгаанд хамрагдагсдын дундаж нас 52.4±13.97 жил, хүйсийн хувьд эрэгтэй 126 (63%), эмэгтэй 74 (37%) байлаа. ГВВ-ийн архаг халдвартай бүлэгт нас (46.68±14.77 жил) бага байх, ялтаст эсийн тоо (227.65±64.75) ихсэх, FIB4 оноо (1.48±1.74) бага байх, бөөрний түүдгэнцэрийн шүүлтийн хурд (100.40±20.73) ихсэх зэрэг үзүүлэлтүүд ГСВ-ийн архаг халдвартай бүлгээс статистикийн ач холбогдол бүхий ялгаатай байв. Олон хүчин зүйлийн регрессийн шинжилгээгээр вирусийн шалтгаант элэгний архаг үрэвсэлтэй өвчтөнүүдэд хүйс (эмэгтэй) (OR-0.397, 95% CI:0.208-0.757, р-0.005), ГСВ-ийн халдвар (OR-0.378, 95% CI:0.200-0.711, р-0.003) болон элэгний фиброзын зэрэг (OR-0.288, 95% CI:0.129-0.646, р-0.003) нь бөөрний түүдгэнцэрийн шүүлтийн хурд буурахад нөлөөлдөг хүчин зүйлүүд болохыг харуулж байна. Дүгнэлт: ГСВ-ийн халдвар авах нь бөөрний түүдгэнцэрийн үйл ажиллагааг бууруулах гол хүчин зүйл болж байна. Эдгээр өвчтөнүүдэд элэгний фиброзын зэрэг нэмэгдэх тусам бөөрний түүдгэнцэрийн шүүлтийн хурд буурч байна.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia
    (2018) ; ;
    Munkh-Orshikh, Dashchirev
    ;
    ;
    Sarangua, Ganbold
    Mongolia is located between Russia and China. The total population of Mongolia as of December 2017 is estimated to be 3.2 million people. According to our previous study results, the prevalence of HBV was 11.8%, and anti-HDV was detected in 4.8% among the HBsAg-positive subjects. Interestingly, most HCV infection is caused by genotype 1b. Among all HBV DNA-positive samples, 98.5% were classified into genotype D, and regarding HDV genotypes, all HDV RNA-positive samples, 100%, were classified into genotype I. The second study is the baseline survey of a Nationwide Cancer Cohort Study. Prevalence of HBsAg was 10.6%. Additionally, HCV infection was observed in 9.9%, and 0.8% were coinfected with HBV and HCV among the general population aged from 10 to 64 years. The third study investigated the population-based prevalence of hepatitis B and C virus in apparently healthy population of Ulaanbaatar city, Mongolia. The anti-HCV prevalence was 9.0%. In addition, the prevalence of HBV was 8.0%. The fourth study is on the prevalence of HCV and coinfections among nurses in a tertiary hospital in Mongolia. The prevalence of HCV was 18.9%. Additionally, HBV infection was observed in 23.1%, and 1.2% were coinfected with HCV and HBV. Mongolia has the highest HCC incidence in the world (78.1/100,000, 3.5* higher than China). As a result, the Mongolia government has launched The National Viral Hepatitis Program, which is a comprehensive program that involves all aspects from prevention to care and disease control to meet a reduction goal for morbidity and mortality due to HBV, HCV, and HDV. Consequently, access to antiviral therapies is now improving in Mongolia. How to cite this article: Baatarkhuu O, Gerelchimeg T, Munkh-Orshikh D, Batsukh B, Sarangua G, Amarsanaa J. Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian J Hepato-Gastroenterol 2018;8(1):57-62.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
    (2020-09)
    Charlton, Michael R
    ;
    Alam, Altaf
    ;
    Shukla, Akash
    ;
    Dashtseren, Bekhbold
    ;
    Lesmana, Cosmas Rinaldi Adithya
    Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from Asia convened, reviewed the literature, and developed the current expert opinion-based review article for the use of TAF in the resource-constrained settings in Asia. This article provides a comprehensive review of two large, phase 3, double-blind, randomized controlled trials of TAF versus TDF in HBeAg-negative (study 0108) and HBeAg-positive (study 0110) chronic HBV patients (> 70% Asians). These studies revealed as follows: (1) non-inferiority for the proportion of patients who had HBV DNA < 29 IU/mL; (2) significantly high rate of normalization of alanine aminotransferase levels; (3) no incidence of resistance; and (4) significantly better bone and renal safety, with TAF vs. TDF up to 144 weeks. Considering the benefits of TAF, the expert panel proposed recommendations for optimizing the use of TAF in Asia, along with guidance on specific patient groups at risk of renal or bone disease suitable for TAF therapy. The guidance provided in this article may help clinicians optimize the use of TAF in Asia.
    Scopus© Citations 49
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia
    (2024) ;
    Badamjav, Tegshjargal
    ;
    ;
    Dashjamts, Gantogtokh
    ;
    BACKGROUND: Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. The relative importance of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in HCC etiology is known to vary greatly from one part of the world to another. Principally, 95% of HCC patients have chronic viral hepatitis, including 53% hepatitis B virus, 38.9% HCV, and 5.6% have HBV/HCV coinfection. Hepatitis D virus (HDV) infection is widely spread in our country, anti-HDV has been found in more than 25% of carriers who have HBsAg. MATERIALS AND METHODS: We analyzed data of patients who had been diagnosed with acute viral hepatitis in the Department of adult hepatitis, National Center for Communicable Diseases in Mongolia from 1952 to 2018. RESULTS: A total of 318,831 cases of acute viral hepatitis were registered in Mongolia between 1981 and 2019, which is 34.9 cases per 10,000 population. Of these, 265,931 cases of acute viral hepatitis A, or 28.6 per 10,000 populations, 48,855 cases of acute viral hepatitis B, or 5.5 cases per 10,000 populations, and 2,607 cases of acute viral hepatitis C, or 0.4 cases per 10,000 populations were recorded. CONCLUSION: The prevalence of viral hepatitis in our country was the highest in 1981-1991, but since 2012, the prevalence of infection has steadily decreased. In Mongolia, since 1960, multifaceted programs and activities to combat viral hepatitis have been successfully implemented at the national level. HOW TO CITE THIS ARTICLE: Badamnachin B, Badamjav T, Dondov G, et al. The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia. Euroasian J Hepato-Gastroenterol 2024;14(1):65-69.